Literature DB >> 21741931

Interleukin-17A promotes early but attenuates established disease in crescentic glomerulonephritis in mice.

Dragana Odobasic1, Poh-Yi Gan, Shaun A Summers, Tim J Semple, Ruth C M Muljadi, Yoichiro Iwakura, A Richard Kitching, Stephen R Holdsworth.   

Abstract

T helper (Th)17 cells might contribute to immune-mediated renal injury. Thus, we sought to define the time course of IL-17A-induced kidney damage and examined the relation between Th17 and Th1 cells in a model of crescentic anti-glomerular basement membrane glomerulonephritis. Renal injury and immune responses were assessed in wild-type and in IL-17A-deficient mice on days 6, 14, and 21 of disease development. On day 6, when mild glomerulonephritis developed, IL-17A-deficient mice were protected from renal injury. On day 14, when more severe disease developed, protection from renal injury due to IL-17A deficiency was less evident. On day 21, when crescentic glomerulonephritis was fully established, disease was enhanced in IL-17A(-/-) mice, with increased glomerular T-cell accumulation and fibrin deposition, and augmented Th1 responses. Mice lacking the Th17-promoting cytokine, IL-23 (p19), also developed more severe disease than wild-type animals on day 21. In contrast, mice deficient in the key Th1-promoting cytokine, IL-12 (p35), had decreased Th1 and increased Th17 responses and developed less severe crescentic glomerulonephritis than wild-type animals. These studies show that IL-17A contributes to early glomerular injury, but it attenuates established crescentic glomerulonephritis by suppressing Th1 responses. They provide further evidence that Th1 cells mediate crescentic injury in this model and that Th1 and Th17 cells counterregulate each other during disease development.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741931      PMCID: PMC3157183          DOI: 10.1016/j.ajpath.2011.05.039

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  The Th17-defining transcription factor RORγt promotes glomerulonephritis.

Authors:  Oliver M Steinmetz; Shaun A Summers; Poh-Yi Gan; Timothy Semple; Stephen R Holdsworth; A Richard Kitching
Journal:  J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 10.121

2.  The IL-27 receptor has biphasic effects in crescentic glomerulonephritis mediated through Th1 responses.

Authors:  Shaun A Summers; Richard K S Phoon; Joshua D Ooi; Stephen R Holdsworth; A Richard Kitching
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis.

Authors:  Poh-Yi Gan; Oliver M Steinmetz; Diana S Y Tan; Kim M O'Sullivan; Joshua D Ooi; Yoichiro Iwakura; A Richard Kitching; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 10.121

Review 4.  Th1 and Th17 cells: adversaries and collaborators.

Authors:  Jesse M Damsker; Anna M Hansen; Rachel R Caspi
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

5.  A protective function for interleukin 17A in T cell-mediated intestinal inflammation.

Authors:  William O'Connor; Masahito Kamanaka; Carmen J Booth; Terrence Town; Susumu Nakae; Yoichiro Iwakura; Jay K Kolls; Richard A Flavell
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

6.  IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance.

Authors:  Teresa Zelante; Antonella De Luca; Pierluigi Bonifazi; Claudia Montagnoli; Silvia Bozza; Silvia Moretti; Maria L Belladonna; Carmine Vacca; Carmela Conte; Paolo Mosci; Francesco Bistoni; Paolo Puccetti; Robert A Kastelein; Manfred Kopf; Luigina Romani
Journal:  Eur J Immunol       Date:  2007-10       Impact factor: 5.532

7.  T-bet deficiency attenuates renal injury in experimental crescentic glomerulonephritis.

Authors:  Richard K S Phoon; A Richard Kitching; Dragana Odobasic; Lynelle K Jones; Timothy J Semple; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

8.  Th1 and Th17 cells induce proliferative glomerulonephritis.

Authors:  Shaun A Summers; Oliver M Steinmetz; Ming Li; Joshua Y Kausman; Timothy Semple; Kristy L Edgtton; Dorin-Bogdan Borza; Hal Braley; Stephen R Holdsworth; A Richard Kitching
Journal:  J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 10.121

9.  Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.

Authors:  Dror Luger; Phyllis B Silver; Jun Tang; Daniel Cua; Zoe Chen; Yoichiro Iwakura; Edward P Bowman; Nicole M Sgambellone; Chi-Chao Chan; Rachel R Caspi
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

10.  IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

Authors:  Mark A Kroenke; Thaddeus J Carlson; Anuska V Andjelkovic; Benjamin M Segal
Journal:  J Exp Med       Date:  2008-06-23       Impact factor: 14.307

View more
  20 in total

1.  CXCL5 drives neutrophil recruitment in TH17-mediated GN.

Authors:  Erik M Disteldorf; Christian F Krebs; Hans-Joachim Paust; Jan-Eric Turner; Geraldine Nouailles; André Tittel; Catherine Meyer-Schwesinger; Gesa Stege; Silke Brix; Joachim Velden; Thorsten Wiech; Udo Helmchen; Oliver M Steinmetz; Anett Peters; Sabrina B Bennstein; Anna Kaffke; Chrystel Llanto; Sergio A Lira; Hans-Willi Mittrücker; Rolf A K Stahl; Christian Kurts; Stefan H E Kaufmann; Ulf Panzer
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

Review 2.  Cytokines: Names and Numbers You Should Care About.

Authors:  Stephen R Holdsworth; Poh-Yi Gan
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-04       Impact factor: 8.237

Review 3.  Psoriasis and Systemic Inflammatory Disorders.

Authors:  Tomoko Tashiro; Yu Sawada
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

4.  Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.

Authors:  S A Summers; D Odobasic; M B Khouri; O M Steinmetz; Y Yang; S R Holdsworth; A R Kitching
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 5.  IL-17 in Renal Immunity and Autoimmunity.

Authors:  Partha S Biswas
Journal:  J Immunol       Date:  2018-12-01       Impact factor: 5.422

6.  Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis.

Authors:  Prapaporn Pisitkun; Hye-Lin Ha; Hongshan Wang; Estefania Claudio; Caitlyn C Tivy; Hua Zhou; Tanya N Mayadas; Gabor G Illei; Ulrich Siebenlist
Journal:  Immunity       Date:  2012-11-01       Impact factor: 31.745

Review 7.  IL-12 and IL-23/Th17 axis in systemic lupus erythematosus.

Authors:  Maddalena Larosa; Margherita Zen; Mariele Gatto; Diogo Jesus; Elisabetta Zanatta; Luca Iaccarino; Luis Inês; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-21

8.  The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice.

Authors:  David T Rodgers; Mairi A McGrath; Miguel A Pineda; Lamyaa Al-Riyami; Justyna Rzepecka; Felicity Lumb; William Harnett; Margaret M Harnett
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

9.  Local IL-17 Production Exerts a Protective Role in Murine Experimental Glomerulonephritis.

Authors:  Sally Hamour; Poh-Yi Gan; Ruth Pepper; Fernanda Florez Barros; Hsu-Han Wang; Kim O'Sullivan; Yoichiro Iwakura; Terence Cook; Charles Pusey; Stephen Holdsworth; Alan Salama
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

Review 10.  T cells in vascular inflammatory diseases.

Authors:  Lucas L Lintermans; Coen A Stegeman; Peter Heeringa; Wayel H Abdulahad
Journal:  Front Immunol       Date:  2014-10-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.